Novo Nordisk Swaps Out Last Cancer Compound For Anti-Inflammatory
This article was originally published in The Pink Sheet Daily
Executive Summary
Refocused Danish pharma drops its inhaled-insulin portfolio, while swapping last oncologic for an anti-inflammatory.
You may also be interested in...
Merrion, Novo Nordisk To Collaborate On Oral Insulin Analogues
Despite giving up on inhaled insulin earlier this year, deal continues Novo Nordisk’s focus on enhancements to insulin formulation and delivery.
Merrion, Novo Nordisk To Collaborate On Oral Insulin Analogues
Despite giving up on inhaled insulin earlier this year, deal continues Novo Nordisk’s focus on enhancements to insulin formulation and delivery.
Novo’s Liraglutide Gets Advisory Committee Review; Is Byetta To Blame?
FDA committee will discuss an NDA for the once-daily GLP-1 analogue March 2, likely pushing back the March 23 PDUFA date.